Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
DeepMatcher® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform. Using AI-based compound-protein interaction modeling, Syntekabio has identif
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants.
CAMBRIDGE, Mass., Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants. The underwritten public
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
424B4 - MetaVia Inc. (0001638287) (Filer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)